open access
The importance of bisoprolol in prevention of heart left ventricular hypertrophy in patients with long term L-thyroxin suppressive therapy, after the operation of differentiated thyroid carcinoma
open access
Abstract
Introduction: Patients with differentiated thyroid carcinoma have to undergo radical surgical treatment, which includes total thyreoidectomy, radioiodine therapy and a life-time supressive therapy with L-thyroxine. The aim of this study was a prospective evaluation of left ventricular hypertrophy during L supressive-thyroxine treatment in patients treated for differentiated thyroid carcinoma.
Material and methods: The examined group comprised 50 patients with differentiated thyroid carcinoma, treated by total thyroidectomy and 131I therapy. Echocardiographic measurements were needed for estimation of left ventricular mass and its index, according to recommendations of American Echocardiography Society.
Results: During two-years long supressive therapy we observed a significant rise in left ventricular mass. In woman group left ventricular mass was increased from 168 ± 39 g to 204 ± 45 g (p < 0.001) and in men from 205 ± 60 to 320 ± 21 g. Likewise, left ventricular mass index was increased in women group from 96 ± 18 g/m² to 116 ± 25 g/m² (p < 0.001) and in men group from 107 ± 37 g/m² to 158 ± 28 g/m². Simultaneous treatment with bisoprolol caused a regression of left myocardial hypertrophy. Already after 6 months of simultaneous treatment with L-tyroxin and bisoprolol, for left ventricular mass was reduced to normal: in woman 165 ± 35 g, and in men to 178 ± 38 g. Analogous results were obtained left ventricular mass index. After 6 months it was reduced to 94 ± 12 g/m² in woman and in men to 132 ± 32 g/m².
Conclusions:
1. In differentiated thyroid cancer patients, treated postoperatively with L-thyroxine supressive therapy, left ventricular hypertrophy is observed already during the first year of supressive therapy and progresses during the next year of treatment.
2 Addition of a beta-adrenergic antagonist to supressive doses of L-thyroxine causes a regression of left ventricular hypertrophy, thus, beta-adrenergic antagonists should be administred in this group of patients.
(Pol J Endocrinol 2007; 58 (5): 384-396)
Abstract
Introduction: Patients with differentiated thyroid carcinoma have to undergo radical surgical treatment, which includes total thyreoidectomy, radioiodine therapy and a life-time supressive therapy with L-thyroxine. The aim of this study was a prospective evaluation of left ventricular hypertrophy during L supressive-thyroxine treatment in patients treated for differentiated thyroid carcinoma.
Material and methods: The examined group comprised 50 patients with differentiated thyroid carcinoma, treated by total thyroidectomy and 131I therapy. Echocardiographic measurements were needed for estimation of left ventricular mass and its index, according to recommendations of American Echocardiography Society.
Results: During two-years long supressive therapy we observed a significant rise in left ventricular mass. In woman group left ventricular mass was increased from 168 ± 39 g to 204 ± 45 g (p < 0.001) and in men from 205 ± 60 to 320 ± 21 g. Likewise, left ventricular mass index was increased in women group from 96 ± 18 g/m² to 116 ± 25 g/m² (p < 0.001) and in men group from 107 ± 37 g/m² to 158 ± 28 g/m². Simultaneous treatment with bisoprolol caused a regression of left myocardial hypertrophy. Already after 6 months of simultaneous treatment with L-tyroxin and bisoprolol, for left ventricular mass was reduced to normal: in woman 165 ± 35 g, and in men to 178 ± 38 g. Analogous results were obtained left ventricular mass index. After 6 months it was reduced to 94 ± 12 g/m² in woman and in men to 132 ± 32 g/m².
Conclusions:
1. In differentiated thyroid cancer patients, treated postoperatively with L-thyroxine supressive therapy, left ventricular hypertrophy is observed already during the first year of supressive therapy and progresses during the next year of treatment.
2 Addition of a beta-adrenergic antagonist to supressive doses of L-thyroxine causes a regression of left ventricular hypertrophy, thus, beta-adrenergic antagonists should be administred in this group of patients.
(Pol J Endocrinol 2007; 58 (5): 384-396)
Keywords
differentiated thyroid carcinoma; L-thyroxin therapy; left ventricular hypertrophy; bisoprolol
Title
The importance of bisoprolol in prevention of heart left ventricular hypertrophy in patients with long term L-thyroxin suppressive therapy, after the operation of differentiated thyroid carcinoma
Journal
Issue
Article type
Original paper
Pages
384-396
Published online
2007-10-16
Page views
641
Article views/downloads
1568
Bibliographic record
Endokrynol Pol 2007;58(5):384-396.
Keywords
differentiated thyroid carcinoma
L-thyroxin therapy
left ventricular hypertrophy
bisoprolol
Authors
Gabriela Matuszewska
Bogdan Marek
Dariusz Kajdaniuk
Brygida Przywara-Chowaniec
Jerzy Jarząb
Barbara Jarząb